- Topline results from pivotal Phase 3 INDIGO trial in Immunoglobulin G4-Related Disease expected around year-end 2025 -
Zenas BioPharma Reports First Quarter 2025 Financial Results and Provides Corporate Updates
Seeking Alpha / 6 hours ago 1 Views
Seeking Alpha / 6 hours ago 1 Views
- Topline results from pivotal Phase 3 INDIGO trial in Immunoglobulin G4-Related Disease expected around year-end 2025 -
Comments